Rapid assessment of CAR T-cell strategies for multiple myeloma with the z-Movi® Cell Avidity Analyzer
In this application note, we highlight cell avidity and in vivo experiments performed in collaboration with the team of Dr. Eric Smith (DanaFarber Cancer Institute) and Prof. Carlos de Larrea (Hospital Clínic Barcelona) and show how one can use the z-Movi to:
- Rapidly identify new, effective CAR T-cell therapy candidates for multiple myeloma through cell avidity measurements.
- Predict in vivo outcomes by comparing cell avidity outcomes between CAR T-cell populations.
- Retrieve high-throughput data from different CAR T-cell populations within 24 hours.
Download a copy of the application note here on the right to discover how you can perform cell avidity analysis assessment to explore and validate CAR T-cell functionality and obtain predictive, reproducible, and rapid results at the single-cell level without compromising cell viability.
